Exact Sciences (NASDAQ:EXAS) PT Raised to $100.00

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price objective lifted by Citigroup from $90.00 to $100.00 in a research note issued to investors on Thursday, The Fly reports. Citigroup’s price objective points to a potential upside of 26.28% from the stock’s previous close.

EXAS has been the subject of a number of other reports. Bank of America boosted their target price on shares of Exact Sciences from $80.00 to $88.00 in a report on Wednesday. Craig Hallum raised shares of Exact Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $55.00 to $85.00 in a research report on Wednesday. Credit Suisse Group reaffirmed a “neutral” rating and issued a $70.00 price target on shares of Exact Sciences in a report on Wednesday, February 22nd. SVB Leerink upped their price target on shares of Exact Sciences from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, January 12th. Finally, UBS Group started coverage on shares of Exact Sciences in a report on Friday, May 5th. They set a “neutral” rating and a $73.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.50.

Exact Sciences Stock Up 1.4 %

Shares of NASDAQ EXAS opened at $79.19 on Thursday. The company has a quick ratio of 2.09, a current ratio of 2.38 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $14.11 billion, a price-to-earnings ratio of -22.37 and a beta of 1.41. The firm has a 50-day moving average price of $66.42 and a 200 day moving average price of $57.76. Exact Sciences has a 52 week low of $29.27 and a 52 week high of $80.75.

Exact Sciences (NASDAQ:EXAS – Get Rating) last posted its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.37. The business had revenue of $602.00 million during the quarter, compared to analyst estimates of $543.18 million. Exact Sciences had a negative net margin of 29.92% and a negative return on equity of 19.76%. The company’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.04) earnings per share. Equities research analysts anticipate that Exact Sciences will post -2.76 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy sold 4,527 shares of the stock in a transaction that occurred on Monday, February 13th. The stock was sold at an average price of $64.55, for a total transaction of $292,217.85. Following the transaction, the chief executive officer now owns 1,173,105 shares in the company, valued at $75,723,927.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Exact Sciences news, insider Jacob A. Orville sold 6,832 shares of Exact Sciences stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $60.29, for a total transaction of $411,901.28. Following the completion of the transaction, the insider now directly owns 16,423 shares of the company’s stock, valued at $990,142.67. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin T. Conroy sold 4,527 shares of Exact Sciences stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $64.55, for a total value of $292,217.85. Following the completion of the transaction, the chief executive officer now directly owns 1,173,105 shares of the company’s stock, valued at $75,723,927.75. The disclosure for this sale can be found here. Insiders have sold a total of 75,513 shares of company stock worth $4,977,321 over the last 90 days. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in shares of Exact Sciences by 213.7% during the 1st quarter. Renaissance Technologies LLC now owns 324,100 shares of the medical research company’s stock worth $21,977,000 after buying an additional 220,800 shares during the period. Prospera Financial Services Inc acquired a new position in Exact Sciences during the 1st quarter worth approximately $230,000. Systematic Financial Management LP acquired a new position in Exact Sciences during the 1st quarter worth approximately $132,000. 1832 Asset Management L.P. acquired a new position in Exact Sciences during the 1st quarter worth approximately $8,836,000. Finally, Cresset Asset Management LLC acquired a new stake in shares of Exact Sciences in the 1st quarter valued at approximately $221,000. 90.30% of the stock is owned by institutional investors.

Exact Sciences Company Profile

(Get Rating)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.